Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
KPV is taken up by intestinal cells via the PepT1 di/ transporter and reduces inflammatory signalling (NF-κB, IL-1β) in epithelial and immune cells. Research suggests KPV's anti-inflammatory effects are largely melanocortin--independent.
02
Research applications
- Inflammatory bowel disease research (colitis models)
- Dermatology and keratinocyte research
- Melanocortin pharmacology
- PepT1 transporter pharmacology
Evidence at a glance
What's behind this profile
3 citations · 2003–2008
- Animal
- 1
- In vitro
- 2
Studies in rodents or other animal models.
Cell, tissue, or biochemical assays outside a living organism.
Publication years
- 03
- 04
- 05
- 06
- 07
- 08
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) α-melanocyte-stimulating hormone peptides
2003
Getting SJ et al. · Journal of Pharmacology and Experimental Therapeutics
- Model
- In vivo — C57BL/6 and recessive yellow e/e mouse peritonitis model
- Sample
- Not reported in abstract
KPV exhibited anti-inflammatory effects in the murine peritonitis model that appeared largely independent of melanocortin , likely involving IL-1β inhibition.
α-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells
2004
Elliott RJ et al. · Journal of Investigative Dermatology
- Model
- In vitro — HaCaT cells and normal human keratinocytes
- Sample
- N/A (cell culture)
KPV was associated with elevated intracellular calcium in human keratinocytes via a pathway independent of the classical cAMP melanocortin- signalling.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
2008
Dalmasso G et al. · Gastroenterology
- Model
- In vitro intestinal cell models + in vivo murine DSS- and TNBS-induced colitis
- Sample
- Not reported in abstract
KPV taken up via the PepT1 transporter reduced inflammatory signalling in intestinal cells and was associated with reduced colitis severity in the murine models used.
Evidence caveats
- Primary clinical evidence in humans is limited. Most published primary work is in vitro or rodent.
- KPV is not approved as a medicine for any indication.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Maintain batch and supplier documentation.
- Research-only inventory; not for human use.
- Limited modern clinical protocol documentation.